Effects of zoledronic acid and ibandronate in the treatment of cancer pain in rats with lung cancer combined with bone metastases

Wang,Gengshen; Chen,Jiuyi; Ma,Ruofei; Xu,Weiyuan; Yan,Chunlu; Niu,Cunliang

doi:10.3892/ol.2018.8804

Effects of zoledronic acid and ibandronate in the treatment of cancer pain in rats with lung cancer combined with bone metastases

Authors:
- Gengshen Wang
- Jiuyi Chen
- Ruofei Ma
- Weiyuan Xu
- Chunlu Yan
- Cunliang Niu
View Affiliations

Affiliations: Department of Orthopaedics, Wuwei People's Hospital, Wuwei, Gansu 733000, P.R. China, Department of Respiratory Medicine, Wuwei People's Hospital, Wuwei, Gansu 733000, P.R. China, Department of Oncological Surgery, Gansu Provincial Cancer Hospital, Wuwei, Gansu 730050, P.R. China, Department of Orthopaedics, Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P.R. China, The Animal Experimental Center, Gansu University of Chinese Medicine, Lanzhou, Gansu 730020, P.R. China
Published online on: May 24, 2018 https://doi.org/10.3892/ol.2018.8804
Pages: 1696-1700
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the study was to investigate the efficiency and safety of zoledronic acid and ibandronate in the treatment of rats with lung cancer combined with bone metastases. A total of 124 rats with lung cancer bone metastasis were established. Rats were randomly divided into A, B and C groups (n=30). Rats in group A were treated with ibandronate combined with zoledronic acid, rats in group B were treated with zoledronic acid monotherapy, and rats in group C were treated with ibandronate monotherapy. Rats in group A were injected subcutaneously with zoledronic acid 0.1 mg/kg and ibandronate 10 µg/kg, once per week for 12 weeks; rats in group B were injected subcutaneously with zoledronic acid, and rats in group C were injected subcutaneously with ibandronate, the same method as the treatment group. The remaining 34 SD rats were not treated to serve as the control group. Treatment efficacy and physical improvement in 8 weeks were observed, and improvement of pain behavior in rats was evaluated to reflect the effect of drug treatment. Of the 30 rats in group A, 25 showed different degrees of remission, 5 rats showed no improvement and the effective rate was 83.3%. Of the 30 rats in group B, 21 showed different degrees of remission, 9 rats showed no improvement and the effective rate was 70%. Of the 30 rats in group C, 20 showed different degrees of remission, 10 rats showed no improvement and the effective rate was 66.7%. Statistically significant differences in total effective rate were found among three groups, and the combined method showed the highest effective rate (P<0.05). Ibandronate combined with zoledronic acid has a good therapeutic effect on cancer pain caused by bone metastases from lung cancer.

View Figures

View References

1	Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E and Bray F: International trends in lung cancer incidence by histological subtype: Adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer. 84:13–22. 2014. View Article : Google Scholar : PubMed/NCBI
2	Tissot C, Couraud S, Tanguy R, Bringuier PP, Girard N and Souquet PJ: Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations. Lung Cancer. 91:23–28. 2016. View Article : Google Scholar : PubMed/NCBI
3	Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al: Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
4	Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al: KEYNOTE-024 Investigators: Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016. View Article : Google Scholar : PubMed/NCBI
5	D'Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, Fulvi A and de Marinis F: Bone and brain metastasis in lung cancer: Recent advances in therapeutic strategies. Ther Adv Med Oncol. 6:101–114. 2014. View Article : Google Scholar : PubMed/NCBI
6	Jung RS, Mittal BR, Santhosh S, Sood A, Bhattacharya A and Kapoor R: Is femoral uptake of Tc99m-methylene diphosphonate on bone scintigraphy in bronchogenic carcinoma an alarming sign: A case report and brief review of literature? Lung India. 31:280–281. 2014. View Article : Google Scholar : PubMed/NCBI
7	Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, et al: Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: An analysis of data from patients with solid tumors. Support Care Cancer. 22:679–687. 2014. View Article : Google Scholar : PubMed/NCBI
8	Murakami H, Yamanaka T, Seto T, Sugio K, Okamoto I, Sawa T, Hirashima T, Takeda K, Atagi S, Fukuoka M, et al: Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group. Cancer Sci. 105:989–995. 2014. View Article : Google Scholar : PubMed/NCBI
9	Dimitroulis IA, Dervas A, Vasileiou S and Toumbis M: Comparative efficacy of ibandronic acid vs. Zoledronic acid in lung cancer patients with skeletal metastases. Do they alleviate the patient? J Thorac Oncol. 9:S203–S204. 2014.
10	LeVasseur N, Clemons M, Hutton B, Shorr R and Jacobs C: Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials. Cancer Treat Rev. 50:183–193. 2016. View Article : Google Scholar : PubMed/NCBI
11	Miller RE, Jones JC, Tometsko M, Blake ML and Dougall WC: RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases. J Thorac Oncol. 9:345–354. 2014. View Article : Google Scholar : PubMed/NCBI
12	Moyer VA: U.S. Preventive Services Task Force: Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 160:330–338. 2014. View Article : Google Scholar : PubMed/NCBI
13	Moolgavkar SH, Holford TR, Levy DT, Kong CY, Foy M, Clarke L, Jeon J, Hazelton WD, Meza R, Schultz F, et al: Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975–2000. J Natl Cancer Inst. 104:541–548. 2012. View Article : Google Scholar : PubMed/NCBI
14	Humphrey L, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, Zakher B, Fu R and Slatore C: Screening for Lung Cancer: Systematic Review to Update the U.S. Preventive Services Task Force Recommendation [Internet]. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. 157:7062013.
15	Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, Timmins H, Wheatley D, Grieve R, Griffiths G, et al: Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: A randomised, open label, non-inferiority phase 3 trial. Lancet Oncol. 15:114–122. 2014. View Article : Google Scholar : PubMed/NCBI
16	Hendriks LE, Hermans BC, van den Beuken-van Everdingen MH, Hochstenbag MM and Dingemans AM: Effect of bisphosphonates, denosumab, and radioisotopes on bone pain and quality of life in patients with non-small cell lung cancer and bone metastases: A systematic review. J Thorac Oncol. 11:155–173. 2016. View Article : Google Scholar : PubMed/NCBI
17	Xie F, Li P, Gong J, Zhang J and Ma J: The bisphosphonate zoledronic acid effectively targets lung cancer cells by inhibition of protein prenylation. Biochem Biophys Res Commun. 467:664–669. 2015. View Article : Google Scholar : PubMed/NCBI
18	Silva SC, Wilson C and Woll PJ: Bone-targeted agents in the treatment of lung cancer. Ther Adv Med Oncol. 7:219–228. 2015. View Article : Google Scholar : PubMed/NCBI
19	Liu J, Huang W, Zhou R, Jia S, Tang W, Luo Y and Zhang J: Bisphosphonates in the treatment of patients with metastatic breast, lung, and prostate cancer: A Meta-analysis. Medicine (Baltimore). 94:e20142015. View Article : Google Scholar : PubMed/NCBI
20	Luedders DW, Steinhoff J, Thill M, Rody A and Bohlmann MK: Lack of difference in acute nephrotoxicity of intravenous bisphosphonates zoledronic acid and ibandronate in women with breast cancer and bone metastases. Anticancer Res. 35:1797–1802. 2015.PubMed/NCBI
21	Qaseem A, Forciea MA, McLean RM and Denberg TD; Clinical Guidelines Committee of the American College of Physicians: Treatment of low bone density or osteoporosis to prevent fractures in men and women: A clinical practice guideline update from the American College of Physicians. Ann Intern Med. 166:818–839. 2017. View Article : Google Scholar : PubMed/NCBI
22	Jamil K, Zacharin M, Foster B and Munns CF: Protocol for a randomised control trial of bisphosphonate (zoledronic acid) treatment in childhood femoral head avascular necrosis due to Perthes disease. BMJ Paediatrics Open. 1:e0000842017.http://bmjpaedsopen.bmj.com/content/1/1/e000084 View Article : Google Scholar : PubMed/NCBI